Hemogenyx Pharmaceuticals Plc

OTCPK:HOPH.F Stock Report

Market Cap: US$69.7m

Hemogenyx Pharmaceuticals Management

Management criteria checks 3/4

Hemogenyx Pharmaceuticals' CEO is Vladislav Sandler, appointed in Dec 2013, has a tenure of 11.83 years. total yearly compensation is £445.00K, comprised of 98.7% salary and 1.3% bonuses, including company stock and options. directly owns 7.84% of the company’s shares, worth $5.47M. The average tenure of the management team and the board of directors is 3.2 years and 8 years respectively.

Key information

Vladislav Sandler

Chief executive officer

UK£445.0k

Total compensation

CEO salary percentage98.65%
CEO tenure11.8yrs
CEO ownership7.8%
Management average tenure3.2yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vladislav Sandler's remuneration changed compared to Hemogenyx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-UK£8m

Mar 31 2025n/an/a

-UK£7m

Dec 31 2024UK£445kUK£439k

-UK£6m

Sep 30 2024n/an/a

-UK£5m

Jun 30 2024n/an/a

-UK£5m

Mar 31 2024n/an/a

-UK£6m

Dec 31 2023UK£397kUK£389k

-UK£7m

Sep 30 2023n/an/a

-UK£7m

Jun 30 2023n/an/a

-UK£7m

Mar 31 2023n/an/a

-UK£6m

Dec 31 2022UK£282kUK£276k

-UK£4m

Sep 30 2022n/an/a

-UK£3m

Jun 30 2022n/an/a

-UK£3m

Mar 31 2022n/an/a

-UK£4m

Dec 31 2021UK£213kUK£206k

-UK£5m

Sep 30 2021n/an/a

-UK£5m

Jun 30 2021n/an/a

-UK£5m

Mar 31 2021n/an/a

-UK£3m

Dec 31 2020UK£205kUK£200k

-UK£2m

Sep 30 2020n/an/a

-UK£2m

Jun 30 2020n/an/a

-UK£2m

Mar 31 2020n/an/a

-UK£2m

Dec 31 2019UK£149kUK£145k

-UK£1m

Sep 30 2019n/an/a

-UK£2m

Jun 30 2019n/an/a

-UK£2m

Mar 31 2019n/an/a

-UK£2m

Dec 31 2018UK£98kUK£94k

-UK£2m

Compensation vs Market: Vladislav's total compensation ($USD597.91K) is about average for companies of similar size in the US market ($USD600.00K).

Compensation vs Earnings: Vladislav's compensation has increased whilst the company is unprofitable.

CEO

Vladislav Sandler (60 yo)

11.8yrs
Tenure
UK£445,000
Compensation

Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...

Leadership Team

NamePositionTenureCompensationOwnership
Vladislav Sandler
Co-Founder11.8yrsUK£445.00k7.84%
$ 5.5m
Alexis Sandler
Independent Co-Founder & Non-Executive Directorno dataUK£60.00k3.5%
$ 2.4m
Koen Van Besien
Clinical Advisor & Medical Director3.2yrsno datano data
Ben Harber
Company Secretaryless than a yearno datano data
3.2yrs
Average Tenure

Experienced Management: HOPH.F's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vladislav Sandler
Co-Founder8yrsUK£445.00k7.84%
$ 5.5m
Alexis Sandler
Independent Co-Founder & Non-Executive Director8yrsUK£60.00k3.5%
$ 2.4m
Koen Van Besien
Clinical Advisor & Medical Directorno datano datano data
H. Shepard
Scientific Advisor7.6yrsno datano data
Peter Redmond
Independent Non-Executive Director10.3yrsUK£58.00k0.26%
$ 181.9k
Marc Feldmann
Independent Chairman & Chairman of Advisory Board8.1yrsUK£49.00kno data
8.0yrs
Average Tenure
75yo
Average Age

Experienced Board: HOPH.F's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/20 03:02
End of Day Share Price 2025/07/23 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.